RAPT Therapeutics (RAPT) Liabilities and Shareholders Equity (2020 - 2024)
Historic Liabilities and Shareholders Equity for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $108.5 million.
- Therapeutics' Liabilities and Shareholders Equity fell 4569.17% to $108.5 million in Q3 2024 from the same period last year, while for Dec 2024 it was $391.5 million, marking a year-over-year decrease of 5351.52%. This contributed to the annual value of $173.3 million for FY2023, which is 3488.99% down from last year.
- Latest data reveals that Therapeutics reported Liabilities and Shareholders Equity of $108.5 million as of Q3 2024, which was down 4569.17% from $127.2 million recorded in Q2 2024.
- In the past 5 years, Therapeutics' Liabilities and Shareholders Equity registered a high of $266.2 million during Q4 2022, and its lowest value of $105.9 million during Q1 2021.
- In the last 5 years, Therapeutics' Liabilities and Shareholders Equity had a median value of $187.5 million in 2022 and averaged $179.5 million.
- Per our database at Business Quant, Therapeutics' Liabilities and Shareholders Equity surged by 7705.9% in 2022 and then plummeted by 4569.17% in 2024.
- Quarter analysis of 5 years shows Therapeutics' Liabilities and Shareholders Equity stood at $119.0 million in 2020, then soared by 66.96% to $198.6 million in 2021, then skyrocketed by 34.02% to $266.2 million in 2022, then plummeted by 34.89% to $173.3 million in 2023, then crashed by 37.42% to $108.5 million in 2024.
- Its Liabilities and Shareholders Equity was $108.5 million in Q3 2024, compared to $127.2 million in Q2 2024 and $155.8 million in Q1 2024.